Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) unit, Shanghai Shangyao No. 1 Biochemical & Pharmaceutical, received drug registration certificates from China's National Medical Products Administration for clevidipine injectable emulsion, according to a Shanghai bourse filing over the weekend.

The Chinese pharmaceutical company's Shanghai shares rose 1% during Monday's morning trade.

The drug is used to treat hypertension in patients for whom oral administration is unsuitable or for whom oral drug therapy is expected to be ineffective.